AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 19502645 — intervention group
Group type: EXPERIMENTAL
Intervention: Revascularization in CABG stratum
Number of subjects: 2368
Study 19502645 — intervention group
Group type: COMPARATOR
Intervention: Medical therapy in CABG stratum
Number of subjects: 2368
Study 19502645 — intervention group
Group type: COMPARATOR
Intervention: Insulin-provision group
Number of subjects: 2368
Study 19502645 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin-sensitization group
Number of subjects: 2368
Study 19504715 — intervention group
Group type: EXPERIMENTAL
Intervention: Biphasic insulin aspart 30/70 (BIAsp 30)
Number of subjects: 748
Study 19505676 — intervention group
Group type: EXPERIMENTAL
Intervention: Ahmed glaucoma valve (AGV) implantation
Number of subjects: 41
Study 19505676 — intervention group
Group type: COMPARATOR
Intervention: Control group (contralateral glaucomatous eyes receiving antiglaucoma medications)
Number of subjects: 41
Study 19506188 — intervention group
Group type: COMPARATOR
Intervention: Sham control
Number of subjects: 321
Study 19506188 — intervention group
Group type: COMPARATOR
Intervention: No-treatment control
Number of subjects: 321
Study 19506189 — intervention group
Group type: EXPERIMENTAL
Intervention: 15-mL bottle
Number of subjects: 139
Study 19506189 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5-mL bottle
Number of subjects: 139
Study 19506189 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall performance
Number of subjects: 139
Study 19506209 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab therapy
Number of subjects: 0
Study 19506561 — intervention group
Group type: EXPERIMENTAL
Intervention: MIF gene expression in freshly isolated adipocytes
Number of subjects: 34
Study 19506561 — intervention group
Group type: EXPERIMENTAL
Intervention: MIF gene expression in cultured preadipocytes
Number of subjects: 34
Study 19506561 — intervention group
Group type: EXPERIMENTAL
Intervention: Adipocyte MIF mRNA concentrations
Number of subjects: 34
Study 19506561 — intervention group
Group type: EXPERIMENTAL
Intervention: Adipocyte diameter
Number of subjects: 34
Study 19507171 — intervention group
Group type: EXPERIMENTAL
Intervention: GATC surveillance for anthracycline-induced cardiotoxicity
Number of subjects: 1836
Study 19507171 — intervention group
Group type: EXPERIMENTAL
Intervention: GATC surveillance for cisplatin-induced hearing impairment
Number of subjects: 1836
Study 19507171 — intervention group
Group type: EXPERIMENTAL
Intervention: GATC surveillance for codeine-induced mortality in breastfed infants
Number of subjects: 1836
Study 19507806 — intervention group
Group type: EXPERIMENTAL
Intervention: OROS hydromorphone (individualized doses), administered once daily.
Number of subjects: 388
Study 19508731 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine dimesylate (LDX) 30, 50, 70 mg/d
Number of subjects: 117
Study 19508731 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 117
Study 19508997 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher intake of DHA (>=64.0 mg/day)
Number of subjects: 2924
Study 19508997 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher intake of EPA (>=42.3 mg/day)
Number of subjects: 2924
Study 19508997 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower dietary glycaemic index (dGI <75.2)
Number of subjects: 2924
Study 19508997 — intervention group
Group type: COMPARATOR
Intervention: Higher DHA intake in placebo group
Number of subjects: 2924
Study 19509175 — intervention group
Group type: EXPERIMENTAL
Intervention: Pazopanib 800 mg once daily
Number of subjects: 63
Study 19509175 — intervention group
Group type: EXPERIMENTAL
Intervention: Pazopanib 300 mg twice daily
Number of subjects: 63
Study 19509175 — intervention group
Group type: EXPERIMENTAL
Intervention: Pazopanib (various doses)
Number of subjects: 63
Study 19515290 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily alcohol use
Number of subjects: 245
Study 19515290 — intervention group
Group type: EXPERIMENTAL
Intervention: Days with sex
Number of subjects: 245
Study 19515473 — intervention group
Group type: EXPERIMENTAL
Intervention: Home BP measured 3 times daily for 1 week using a validated oscillometric monitor.
Number of subjects: 0
Study 19515473 — intervention group
Group type: EXPERIMENTAL
Intervention: Home BP measured during each third of the interdialytic interval.
Number of subjects: 0
Study 19515473 — intervention group
Group type: COMPARATOR
Intervention: Ambulatory BP monitoring.
Number of subjects: 0
Study 19515473 — intervention group
Group type: EXPERIMENTAL
Intervention: Probing dry weight.
Number of subjects: 0
Study 19515473 — intervention group
Group type: EXPERIMENTAL
Intervention: Home BP compared to ambulatory BP.
Number of subjects: 0
Study 19520420 — intervention group
Group type: EXPERIMENTAL
Intervention: PLD 30 mg/m² followed by carboplatin AUC 5 mg/mL/minute every 4 weeks
Number of subjects: 58
Study 19524963 — intervention group
Group type: EXPERIMENTAL
Intervention: Denosumab (180 mg subcutaneous every 4 weeks or every 12 weeks)
Number of subjects: 50
Study 19524963 — intervention group
Group type: COMPARATOR
Intervention: Intravenous bisphosphonates (every 4 weeks)
Number of subjects: 50
Study 19524963 — intervention group
Group type: EXPERIMENTAL
Intervention: Denosumab
Number of subjects: 50
Study 19527724 — intervention group
Group type: EXPERIMENTAL
Intervention: pegylated interferon alfa-2a and ribavirin
Number of subjects: 260
Study 19528536 — intervention group
Group type: EXPERIMENTAL
Intervention: Busulfan/fludarabine/antithymocyte globulin RIC regimen
Number of subjects: 47
Study 19529780 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG revaccination (BCG-BCG)
Number of subjects: 13
Study 19529780 — intervention group
Group type: COMPARATOR
Intervention: BCG-MVA85A
Number of subjects: 13
Study 19531247 — intervention group
Group type: EXPERIMENTAL
Intervention: Copy-number variation (CNV) in BMPR2
Number of subjects: 97
Study 19531247 — intervention group
Group type: COMPARATOR
Intervention: Control group (35 controls)
Number of subjects: 97
Study 19535054 — intervention group
Group type: EXPERIMENTAL
Intervention: APACHE II score
Number of subjects: 1019
Study 19535054 — intervention group
Group type: EXPERIMENTAL
Intervention: Unit increase in APACHE II score
Number of subjects: 1019
Study 19535054 — intervention group
Group type: EXPERIMENTAL
Intervention: Components of APACHE II (temperature, serum creatinine, Glasgow Coma Scale)
Number of subjects: 1019
Study 19535054 — intervention group
Group type: COMPARATOR
Intervention: ISS score
Number of subjects: 1019
Study 19535054 — intervention group
Group type: COMPARATOR
Intervention: TRISS score
Number of subjects: 1019
Study 19535099 — intervention group
Group type: EXPERIMENTAL
Intervention: Myofascial physical therapy
Number of subjects: 48
Study 19535099 — intervention group
Group type: COMPARATOR
Intervention: Global therapeutic massage
Number of subjects: 48
Study 19536844 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyurea
Number of subjects: 0
Study 19539144 — intervention group
Group type: EXPERIMENTAL
Intervention: Levosimendan
Number of subjects: 1038
Study 19539144 — intervention group
Group type: COMPARATOR
Intervention: Dobutamine
Number of subjects: 1038
Study 19539214 — intervention group
Group type: EXPERIMENTAL
Intervention: Filgrastim
Number of subjects: 309
Study 19540516 — intervention group
Group type: EXPERIMENTAL
Intervention: MKS3 mutations
Number of subjects: 3
Study 19540516 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetic resonance imaging
Number of subjects: 3
Study 19540952 — intervention group
Group type: EXPERIMENTAL
Intervention: H5N1 VN 2004 AA ca at 10(7.5) TCID(50)
Number of subjects: 59
Study 19540952 — intervention group
Group type: EXPERIMENTAL
Intervention: H5N1 VN 2004 AA ca at 10(6.7) TCID(50)
Number of subjects: 59
Study 19540952 — intervention group
Group type: EXPERIMENTAL
Intervention: H5N1 HK 2003 AA ca
Number of subjects: 59
Study 19541818 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic kidney disease (CKD) patients with lower eGFR
Number of subjects: 3612
Study 19541818 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic kidney disease (CKD) patients
Number of subjects: 3612
Study 19542735 — intervention group
Group type: EXPERIMENTAL
Intervention: Lanreotide Autogel (ATG) 120 mg injections every 4-8 weeks
Number of subjects: 51
Study 19545437 — intervention group
Group type: EXPERIMENTAL
Intervention: Collagen fleece-bound fibrin sealant
Number of subjects: 3098
Study 19545857 — intervention group
Group type: EXPERIMENTAL
Intervention: Single subanesthetic dose of intravenous ketamine
Number of subjects: 26
Study 19545857 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrice-weekly ketamine infusions over a 12-day period
Number of subjects: 26
Study 19546056 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous pramlintide infusion (CSPI) at 9 microg/h with premeal bolus doses starting at 15 microg and titrated to 60 microg
Number of subjects: 11
Study 19546477 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 92
Study 19546477 — intervention group
Group type: COMPARATOR
Intervention: Prednisone
Number of subjects: 92
Study 19546476 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-azacytidine and entinostat
Number of subjects: 30
Study 19548294 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine 60 mg daily
Number of subjects: 15
Study 19549699 — intervention group
Group type: EXPERIMENTAL
Intervention: Quantitative contrast stress echocardiography (CSE) before PCI
Number of subjects: 33
Study 19549699 — intervention group
Group type: EXPERIMENTAL
Intervention: Quantitative contrast stress echocardiography (CSE) after successful PCI
Number of subjects: 33
Study 19549699 — intervention group
Group type: EXPERIMENTAL
Intervention: Quantitative contrast stress echocardiography (CSE) in regions with restenosis after PCI
Number of subjects: 33
Study 19549740 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH antagonist (NAL-GLU, 150 microg/kg sc) followed by GnRH doses of 25, 75, 250, or 750 ng/kg iv every 4 h
Number of subjects: 19
Study 19549995 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic prescribing (53% overall)
Number of subjects: 3402
Study 19549995 — intervention group
Group type: COMPARATOR
Intervention: No antibiotics prescribed (control group)
Number of subjects: 3402
Study 19553641 — intervention group
Group type: EXPERIMENTAL
Intervention: Olaparib (200 mg twice daily)
Number of subjects: 60
Study 19553641 — intervention group
Group type: EXPERIMENTAL
Intervention: Olaparib (400 mg twice daily)
Number of subjects: 60
Study 19553641 — intervention group
Group type: EXPERIMENTAL
Intervention: Olaparib (600 mg twice daily)
Number of subjects: 60
Study 19553641 — intervention group
Group type: EXPERIMENTAL
Intervention: Olaparib (10 mg daily for 2 of every 3 weeks)
Number of subjects: 60
Study 19554094 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural Eggshell Membrane (NEM) 500 mg once daily for four weeks (single-arm trial)
Number of subjects: 39
Study 19554094 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural Eggshell Membrane (NEM) 500 mg once daily for four weeks (double-arm trial)
Number of subjects: 39
Study 19555842 — intervention group
Group type: EXPERIMENTAL
Intervention: Copeptin levels at presentation
Number of subjects: 487
Study 19555842 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of troponin T and copeptin
Number of subjects: 487
Study 19555842 — intervention group
Group type: EXPERIMENTAL
Intervention: Copeptin <14 pmol/l and troponin T < or =0.01 microg/l
Number of subjects: 487
Study 19555845 — intervention group
Group type: EXPERIMENTAL
Intervention: Synergy Pocket Micro-pump device (CircuLite, Inc.)
Number of subjects: 17
Study 19555921 — intervention group
Group type: EXPERIMENTAL
Intervention: Descemet membrane endothelial keratoplasty (DMEK)
Number of subjects: 26
Study 19556425 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunotherapy (autologous leukemia cells with GM-CSF-secreting K562 cells)
Number of subjects: 54
Study 19556425 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunotherapy-treated patients (28 patients)
Number of subjects: 54
Study 19556425 — intervention group
Group type: EXPERIMENTAL
Intervention: All patients
Number of subjects: 54
Study 19556425 — intervention group
Group type: EXPERIMENTAL
Intervention: Posttreatment induction of delayed-type hypersensitivity reactions
Number of subjects: 54
Study 19556425 — intervention group
Group type: EXPERIMENTAL
Intervention: Decrease in WT1 transcripts after first immunotherapy dose
Number of subjects: 54
Study 19557149 — intervention group
Group type: EXPERIMENTAL
Intervention: Best practice implementation enhancement program
Number of subjects: 697
Study 19561459 — intervention group
Group type: EXPERIMENTAL
Intervention: Saline-linked surface radiofrequency ablation (SLSRFA) at 45 W/4 cm for 9 minutes
Number of subjects: 27
Study 19561459 — intervention group
Group type: EXPERIMENTAL
Intervention: Saline-linked surface radiofrequency ablation (SLSRFA) at various power/diameter combinations (10 W/1 cm; 15 W/2 cm; 45 W/4 cm) for 9 minutes
Number of subjects: 27
Study 19561459 — intervention group
Group type: EXPERIMENTAL
Intervention: Saline-linked surface radiofrequency ablation (SLSRFA) at 45 W/4 cm
Number of subjects: 27
Study 19561459 — intervention group
Group type: EXPERIMENTAL
Intervention: Saline-linked surface radiofrequency ablation (SLSRFA)
Number of subjects: 27
Study 19562254 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib plus sirolimus (150 mg and 5 mg for patients not on concurrent CYP3A-inducing anti-epileptics; 450 mg and 10 mg for patients on EIAEDS)
Number of subjects: 32
Study 19562254 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib plus sirolimus
Number of subjects: 32
Study 19564755 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel biomechanical device
Number of subjects: 19
Study 19565495 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-TNF monoclonal antibody therapy (infliximab, adalimumab)
Number of subjects: 69
Study 19565495 — intervention group
Group type: COMPARATOR
Intervention: Anti-TNF monoclonal antibody therapy (etanercept)
Number of subjects: 69
Study 19565495 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to infliximab versus etanercept
Number of subjects: 69
Study 19565495 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to adalimumab versus etanercept
Number of subjects: 69
Study 19565560 — intervention group
Group type: EXPERIMENTAL
Intervention: PT-led classes
Number of subjects: 351
Study 19565560 — intervention group
Group type: COMPARATOR
Intervention: CEI-led classes
Number of subjects: 351
Study 19567517 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoledronic acid (ZOL) 5 mg
Number of subjects: 7765
Study 19567517 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7765
Study 19569973 — intervention group
Group type: EXPERIMENTAL
Intervention: 90 microg H5N1 A/Vietnam/1203/04 vaccine
Number of subjects: 75
Study 19569973 — intervention group
Group type: EXPERIMENTAL
Intervention: 120 microg H5N1 A/Vietnam/1203/04 vaccine
Number of subjects: 75
Study 19569973 — intervention group
Group type: EXPERIMENTAL
Intervention: 180 microg H5N1 A/Vietnam/1203/04 vaccine
Number of subjects: 75
Study 19571722 — intervention group
Group type: EXPERIMENTAL
Intervention: Early sex (intercourse <42 days after circumcision)
Number of subjects: 1246
Study 19571722 — intervention group
Group type: COMPARATOR
Intervention: No early sex (control group)
Number of subjects: 1246
Study 19571722 — intervention group
Group type: EXPERIMENTAL
Intervention: Incomplete wound healing
Number of subjects: 1246
Study 19571722 — intervention group
Group type: COMPARATOR
Intervention: Complete wound healing (control group)
Number of subjects: 1246
Study 19573495 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg oral lorazepam
Number of subjects: 36
Study 19573495 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 19573495 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined measures for heterozygotes
Number of subjects: 36
Study 19574030 — intervention group
Group type: EXPERIMENTAL
Intervention: SSRIs or venlafaxine
Number of subjects: 82
Study 19576329 — intervention group
Group type: EXPERIMENTAL
Intervention: Guideline-recommended therapies (angiotensin-converting enzyme inhibitor/angiotensin receptor blocker and beta-blocker use)
Number of subjects: 48612
Study 19576329 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospital discharge instructions
Number of subjects: 48612
Study 19576329 — intervention group
Group type: EXPERIMENTAL
Intervention: Length of stay
Number of subjects: 48612
Study 19576329 — intervention group
Group type: EXPERIMENTAL
Intervention: All guideline-recommended cardiac medications prescribed at discharge
Number of subjects: 48612
Study 19576329 — intervention group
Group type: EXPERIMENTAL
Intervention: In-hospital mortality risk
Number of subjects: 48612
Study 19576329 — intervention group
Group type: EXPERIMENTAL
Intervention: Postdischarge mortality risk
Number of subjects: 48612
Study 19576664 — intervention group
Group type: EXPERIMENTAL
Intervention: One-year lifestyle intervention in 29 obese children
Number of subjects: 89
Study 19576664 — intervention group
Group type: COMPARATOR
Intervention: Waist circumference (WC)
Number of subjects: 89
Study 19576664 — intervention group
Group type: COMPARATOR
Intervention: SDS-BMI
Number of subjects: 89
Study 19576664 — intervention group
Group type: COMPARATOR
Intervention: UMA
Number of subjects: 89
Study 19576664 — intervention group
Group type: COMPARATOR
Intervention: Changes of WC
Number of subjects: 89
Study 19576664 — intervention group
Group type: COMPARATOR
Intervention: Change of SDS-BMI and UMA
Number of subjects: 89
Study 19577985 — intervention group
Group type: EXPERIMENTAL
Intervention: Expanded use of TAXUS Express Stent
Number of subjects: 7492
Study 19577985 — intervention group
Group type: COMPARATOR
Intervention: Simple use of TAXUS Express Stent
Number of subjects: 7492
Study 19581352 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with clinically significant pleural effusion (6.6% of total patients, 192 patients)
Number of subjects: 2892
Study 19581352 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with pleural effusion (192 patients)
Number of subjects: 2892
Study 19581810 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimized treatment with oral lansoprazole
Number of subjects: 67
Study 19581810 — intervention group
Group type: COMPARATOR
Intervention: Antrectomy
Number of subjects: 67
Study 19581810 — intervention group
Group type: COMPARATOR
Intervention: Basal acid output >5 mmol/h
Number of subjects: 67
Study 19581810 — intervention group
Group type: COMPARATOR
Intervention: Poor compliance
Number of subjects: 67
Study 19581810 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocol driven charges
Number of subjects: 67
Study 19583857 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast-track intervention for 8 weeks
Number of subjects: 20
Study 19583857 — intervention group
Group type: COMPARATOR
Intervention: Standard care during 8-week waiting period
Number of subjects: 20
Study 19583857 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast-track trial methodology
Number of subjects: 20
Study 19583857 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline/outcome measures
Number of subjects: 20
Study 19584400 — intervention group
Group type: EXPERIMENTAL
Intervention: ABVE-PC (doxorubicin, bleomycin, vincristine, etoposide, prednisone, cyclophosphamide) administered every 21 days
Number of subjects: 216
Study 19584400 — intervention group
Group type: EXPERIMENTAL
Intervention: ABVE-PC followed by 21 Gy radiation for rapid early responders
Number of subjects: 216
Study 19584400 — intervention group
Group type: EXPERIMENTAL
Intervention: ABVE-PC followed by 21 Gy radiation for slow early responders after 2 additional cycles
Number of subjects: 216
Study 19586800 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunitinib (50 mg/day for 4 weeks, followed by 2 weeks off treatment)
Number of subjects: 37
Study 19586800 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunitinib (50 mg/day)
Number of subjects: 37
Study 19587341 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraarticular delivery of a TNF-alpha antagonist via an AAV type 2 delivery system
Number of subjects: 1
Study 19587341 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent anti-TNF-alpha therapy and other immunosuppressive therapy
Number of subjects: 1
Study 19587363 — intervention group
Group type: EXPERIMENTAL
Intervention: Bariatric surgery
Number of subjects: 27
Study 19587528 — intervention group
Group type: EXPERIMENTAL
Intervention: Mtb72F/AS02A vaccine (3 doses according to a 0-1-2 months schedule)
Number of subjects: 0
Study 19587528 — intervention group
Group type: EXPERIMENTAL
Intervention: Mtb72F/AS02A vaccine
Number of subjects: 0
Study 19593212 — intervention group
Group type: EXPERIMENTAL
Intervention: SNPs in IL15, NPY2R, and NPY5R in blacks
Number of subjects: 885
Study 19593212 — intervention group
Group type: EXPERIMENTAL
Intervention: SNPs in NPY1R, NPY2R, NPY5R, CPE, IL15, and SFRP2
Number of subjects: 885
Study 19593212 — intervention group
Group type: EXPERIMENTAL
Intervention: SNPs in NPY2R, NPY5R, and SFRP2 in whites
Number of subjects: 885
Study 19594547 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral fludarabine in combination with rituximab (375 mg/m² rituximab on day 1, 40 mg/m² oral fludarabine once daily on days 1-5 every 28 days for up to six cycles)
Number of subjects: 41
Study 19594547 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral fludarabine in combination with rituximab
Number of subjects: 41
Study 19594946 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-6 M Dexamethasone (Dex)
Number of subjects: 35
Study 19594946 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal controls)
Number of subjects: 35
Study 19594946 — intervention group
Group type: EXPERIMENTAL
Intervention: Steroid-sensitive (SS) patients
Number of subjects: 35
Study 19597050 — intervention group
Group type: EXPERIMENTAL
Intervention: Systematic clinical testing including cardiac magnetic resonance imaging, signal-averaged ECG, exercise testing, drug challenge, and selective electrophysiological testing.
Number of subjects: 63
Study 19597050 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted genetic testing.
Number of subjects: 63
Study 19597050 — intervention group
Group type: EXPERIMENTAL
Intervention: Family screening of 64 family members of these patients.
Number of subjects: 63
Study 19597050 — intervention group
Group type: EXPERIMENTAL
Intervention: Systematic clinical testing (overall approach).
Number of subjects: 63
Study 19601706 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-articular Hylan G-F 20 injections
Number of subjects: 32
Study 19602710 — intervention group
Group type: EXPERIMENTAL
Intervention: ITD integration site in the beta1-sheet of the tyrosine kinase domain-1 (TKD1)
Number of subjects: 241